Mycotoxin Testing Guide: Measuring Your Body Burden from Mold Exposure

When you live or work in a building contaminated with mold, the toxic byproducts that fungi produce — mycotoxins — do not simply stay in the air. They are inhaled, ingested with contaminated dust, and absorbed dermally. Over time, certain mycotoxins accumulate in fat tissue, the liver, and other organs, creating what researchers call a body burden. Unlike environmental air testing that measures what is in the building, mycotoxin body-burden testing attempts to measure what is already inside you.

This guide explains every major testing method available to patients and clinicians in the United States, what each test actually measures, the mycotoxins each panel covers, and the important limitations that physicians and patients must understand before interpreting results. We also cover CIRS (Chronic Inflammatory Response Syndrome) biomarkers that — while not direct mycotoxin assays — are used alongside these panels to assess downstream physiological damage.

What Mycotoxin Body Burden Testing Actually Measures

The Major Mycotoxins Targeted by Commercial Panels

Understanding what compounds are being measured helps you assess whether a panel matches your suspected exposure. The mycotoxins most commonly associated with indoor water-damaged buildings include:

• Ochratoxin A (OTA) — Produced primarily by Aspergillus ochraceus and Penicillium verrucosum; nephrotoxic, immunosuppressive, and classified as a possible human carcinogen (IARC Group 2B). One of the most commonly detected mycotoxins in urine panels.
• Trichothecenes (Type A and B) — A large family produced by Stachybotrys chartarum, Fusarium, and Trichothecium. Includes satratoxin G and H (macrocyclic trichothecenes unique to Stachybotrys), roridin A, and verrucarin A. Highly cytotoxic; disrupt protein synthesis.
• Aflatoxins (B1, B2, G1, G2) — Primarily associated with Aspergillus flavus and A. parasiticus; less common in water-damaged buildings but detectable in patients with dietary exposure from contaminated grains or nuts. Aflatoxin B1 is the most potent natural hepatocarcinogen known.
• Zearalenone (ZEA) — Produced by Fusarium species; estrogenic compound that can disrupt endocrine function. More common in agricultural contexts but occasionally found in water-damaged grain-based building materials.
• Fumonisins (B1, B2) — Fusarium-derived; primarily a food-safety concern but detected in some body burden panels.
• Citrinin — Co-produced with ochratoxin A by some Penicillium and Aspergillus species; nephrotoxic.
• Mycophenolic acid — Produced by Penicillium brevicompactum; immunosuppressive (it is also the basis for the pharmaceutical immunosuppressant mycophenolate mofetil).
• Gliotoxin — Produced by Aspergillus fumigatus; potent immunosuppressive compound; elevated in patients with invasive aspergillosis.

The Four Major Commercial Urine Mycotoxin Panels

CIRS Biomarker Panel: Downstream Effects, Not Direct Mycotoxin Measurement

In clinical practices following Dr. Ritchie Shoemaker's Surviving Mold protocol, practitioners often order a set of blood biomarkers collectively called the "CIRS panel." These tests do not measure mycotoxins directly — they measure the inflammatory and neuroendocrine dysregulation that chronic mold and biotoxin exposure can trigger in genetically susceptible individuals (specifically those with HLA-DR/DQ haplotypes that impair biotoxin clearance).

Key CIRS biomarkers include:

• TGF-beta-1 (Transforming Growth Factor Beta-1) — An immunoregulatory cytokine. Elevated TGF-beta-1 is associated with CIRS and can contribute to autoimmune-like symptoms, lung fibrosis, and immune dysregulation. Normal range is typically below 2,380 pg/mL.
• C4a (Complement Component 4a) — A split product of the complement cascade. Markedly elevated C4a (above 2,830 ng/mL) is a hallmark biomarker in CIRS patients and is associated with ongoing innate immune activation.
• MMP-9 (Matrix Metalloproteinase-9) — Elevated MMP-9 indicates inflammatory tissue remodeling. In CIRS, elevated MMP-9 is associated with symptoms such as muscle pain, joint pain, and neurological symptoms. Normal is typically below 332 ng/mL.
• VIP (Vasoactive Intestinal Polypeptide) — A neuropeptide that tends to be low or suppressed in CIRS patients. VIP deficiency is associated with fatigue, exercise intolerance, and shortness of breath in CIRS.
• MSH (Melanocyte-Stimulating Hormone) — Often low in CIRS. MSH deficiency correlates with sleep disruption, chronic pain, and susceptibility to staph biofilm colonization.

Mycotoxin Testing Comparison Table

How to Interpret Elevated Mycotoxin Test Results

Receiving a result showing elevated mycotoxin levels raises immediate questions, but interpretation requires caution. Here are the key principles:

Reference Ranges Are Not Firmly Established

Unlike clinical tests with decades of validation (such as a lipid panel or HbA1c), mycotoxin body burden reference ranges are established by each individual laboratory from their own patient and control populations. Different laboratories may use different units (ppt, ppb, creatinine-adjusted), different antibodies in ELISA assays, and different extraction protocols — meaning results are not directly comparable across laboratories.

Creatinine Correction

Most urine mycotoxin results should be adjusted for urine creatinine concentration to account for hydration status. A highly dilute urine sample will produce artificially low mycotoxin readings; a concentrated sample will produce artificially high readings. Look for creatinine-adjusted values (reported per gram creatinine) rather than absolute concentrations when comparing serial tests.

Provocation vs. Non-Provocation Testing

Some practitioners recommend collecting urine after a "provocation" step — such as glutathione supplementation, sauna therapy, or cholestyramine — arguing that these interventions mobilize stored mycotoxins into circulation and urine. Provocation testing is controversial and not standardized. It may increase detection but also increases the risk of artificially elevated readings in people without significant body burden. The professional medical community has not reached consensus on provocation protocols.

What a Positive Result Tells You — and What It Does Not

A positive urine mycotoxin test indicates that your body is excreting a detectable quantity of the measured compound. It does not by itself:

• Establish the source of exposure (diet, building mold, occupational)
• Quantify total body burden or degree of organ damage
• Diagnose CIRS or any other specific clinical syndrome
• Predict symptom severity or treatment outcome

Results must always be interpreted in the context of a detailed exposure history, symptom timeline, physical examination, and corroborating environmental testing of the patient's living and work spaces.

The Limitations of Mycotoxin Body Burden Testing

Any patient or clinician using these tests needs to understand several fundamental limitations that the laboratories themselves acknowledge in their fine print:

No FDA Clearance for Clinical Diagnosis

The FDA has not cleared or approved any urine or blood mycotoxin test for use as a clinical diagnostic assay. All panels described above are laboratory-developed tests (LDTs) regulated under CLIA (Clinical Laboratory Improvement Amendments), which sets standards for laboratory operations but does not involve independent FDA review of clinical accuracy claims. This does not mean the tests are worthless — it means that the evidence base is different from that required for FDA-cleared IVDs, and patients and physicians should understand this distinction.

Cross-Reactivity in ELISA Assays

ELISA (enzyme-linked immunosorbent assay) methodology uses antibodies to detect mycotoxins. These antibodies can cross-react with structurally similar compounds, potentially generating false positives. LC-MS/MS confirmation — used by some panels — reduces this risk substantially by providing molecular mass confirmation, but adds cost.

Dietary vs. Building Sources

Aflatoxins, fumonisins, and ochratoxin A are also present as food contaminants in corn, peanuts, tree nuts, coffee, dried fruit, and grains. A positive result for these compounds on a urine panel may reflect dietary exposure rather than building mold exposure. When ordering these panels, clinicians should obtain a detailed dietary history alongside building history.

Insurance Coverage

Major health insurers including Medicare, Medicaid, and most commercial carriers do not cover mycotoxin body burden tests. Patients typically pay out of pocket. Some practitioners offer discount codes or tiered panels to reduce cost. Flexible Spending Account (FSA) and Health Savings Account (HSA) funds may be applicable — verify with your specific plan.

Mold Species, Mycotoxin Production, and Testing Relevance

Not all mold species produce mycotoxins, and not all mycotoxin-producing species are equally dangerous. The following relationship is important for understanding test interpretation:

• Stachybotrys chartarum (black mold) — Produces macrocyclic trichothecenes (satratoxin G, satratoxin H, roridin A, isosatratoxin F). These are detected by trichothecene panels in RealTime, GPL-MycoTOX, and Vibrant Wellness panels.
• Aspergillus and Penicillium species — Primary producers of ochratoxin A, gliotoxin (Aspergillus fumigatus), citrinin, and mycophenolic acid. The most common molds in water-damaged homes; their mycotoxins are detectable on all major panels.
• Chaetomium globosum — Produces chaetoglobosin A, sterigmatocystin, and other compounds. Detected on newer expanded versions of GPL-MycoTOX and Vibrant panels. Often found in heavily water-damaged drywall alongside Stachybotrys.
• Fusarium species — Produce zearalenone, fumonisins, and deoxynivalenol (DON). More common in agricultural settings than in typical water-damaged homes, but can be found in buildings with severe moisture intrusion affecting grain-based materials.

Related Resources for Mold Health Investigation

Understanding mycotoxin body burden testing is one piece of a broader health investigation. The following guides on this site provide additional context:

• How Mold Affects Your Immune System — the immunological mechanisms behind CIRS and mold illness
• Professional Mold Testing Guide — environmental testing methods for your building
• Mold and Kidney Health — ochratoxin A's nephrotoxic effects and what patients need to know
• Mold and Liver Disease — aflatoxin hepatotoxicity and liver biomarkers in mold-exposed patients
• Mold and the Brain — neurotoxic effects of trichothecenes and cognitive symptoms in CIRS
• Mold and Chronic Fatigue Syndrome — the overlap between CIRS, ME/CFS, and mold illness
• Mold Illness Symptoms Guide — comprehensive symptom checklist for mold-exposed patients
• DIY Mold Testing Guide — what home test kits can and cannot tell you
• Black Mold Symptoms — Stachybotrys-specific health effects and trichothecene toxicity
• Mold Inspection Guide — what to expect from a professional mold assessment

Frequently Asked Questions About Mycotoxin Testing

Working with a CIRS-Literate Physician

Because mycotoxin body burden testing sits in a complex space between conventional medicine and functional/integrative medicine, finding the right physician is important. The Surviving Mold physician directory lists practitioners trained in the Shoemaker protocol. The American Academy of Environmental Medicine (AAEM) also maintains a referral network of physicians experienced in environmental illness.

Comprehensive evaluation for mold-related illness typically includes: a detailed exposure history, the HLA-DR haplotype test (to determine biotoxin susceptibility), the Visual Contrast Sensitivity (VCS) test, the CIRS biomarker panel, and — when indicated — a urine mycotoxin panel from one of the laboratories described above.

Throughout this process, the single most important intervention remains removing the exposure. No amount of binders, antifungals, or supplements will fully resolve CIRS or mycotoxin body burden in a patient who continues to inhabit a contaminated building. If you have not yet confirmed whether your home or workplace is free of mold contamination, that investigation must happen first.

For professional mold inspection and remediation services, call our 24/7 line: (332) 220-0303. Our network of certified mold remediation professionals serves clients nationwide and can coordinate same-day emergency response when needed.

See also: Mold Remediation Cost Guide | The Remediation Process Explained | Mold and Headaches | Mold and Asthma | Mycotoxin Health Effects Guide